The U.S. Embassy hosted a seminar introducing the results of a recent report on the status of the cystic fibrosis treatment in the Czech Republic. Cystic fibrosis is a genetic disorder that causes severe damage to the lungs, digestive system and other organs in the body. Although there is no cure for this rare disease, the treatment can ease symptoms, reduce complications and improve quality of life. The seminar was followed by a lively discussion on the future of care among medical professionals and patient representatives as well as the Ministry of Health and insurance companies.
Acting Deputy Chief of Mission Leah Pease said: “Although the pandemic overshadowed just about every aspect of our lives, those struggling with chronic and rare diseases continued to fight their own battles, but with a new layer of fear from a ruthless virus. Research on cystic fibrosis persisted regardless of the Covid challenge. Funding research on innovative therapies is our best investment to positively impact the lives of patients in the Czech Republic and around the world. The research – especially directed towards rare diseases – can be a challenge, but the results can be truly life changing.”
The event was co-organized and supported by Vertex Pharmaceuticals, a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.
